These sales are routine tax-motivated transactions and carry no informational signal. UTHR has strong analyst sentiment and no material insider selling signal. Monitor the next earnings release and any change in the ongoing share buyback or pipeline developments for directional cues.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 26 $575.25entry
- T+1 · 6mo ago −1.31%α −1.32% · $567.74
- T+5 · 6mo ago −6.14%α −7.36% · $539.91
- T+20 · 5mo ago −5.38%α −3.11% · $544.33
- T+60 · 3mo ago −8.35%α −10.81% · $527.21
Price Chart
How similar events traded
Executive Summary
Three UTHR insiders including the CEO, CFO, and EVP & General Counsel executed a series of option exercises and small open-market sales (total ~$331K) over May 18-21, 2026. The aggregate dollar value is negligible relative to the $24.0B market cap (~0.0014%), and the trades follow a pattern of near-simultaneous multi-leg option exercises with de minimis share sales, consistent with routine tax-withholding or cashless-exercise settlements, not informed selling.
Key Financial Metrics
Key Facts
- Three insiders, CEO Martine A. Rothblatt, CFO James Edgemond, and EVP Paul A. Mahon, sold a combined ~$331K of shares on the open market.
- Sales are tiny relative to market cap (0.0014% of $24.0B), below the 0.1% threshold for materiality.
- Every sale is paired with a simultaneous derivative exercise (option exercise at $0 to $146.03), indicating a tax-withholding or cashless exercise pattern.
- All sales occurred within a 4-day window (May 18-21), consistent with a blackout-window opening post-earnings.
- The common stock has been strong, with analyst consensus 77% bullish and a prior cluster of sells totaling the same $331K noted in the 30d snapshot, this appears to be a recurring quarterly pattern.
Financial Impact
Total insider sales of ~$331K, representing 0.0014% of the $24.0B market cap, economically trivial.
Risk Factors
- No material risk indicated from this insider activity
- The $24B market cap with 77% bullish consensus already prices in continued execution risk on the PAH (pulmonary arterial hypertension) portfolio and potential generic competition for Remodulin/Tyvaso.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1779484617555 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers